knowledge -WSS

knowledge

author：focus 2025-10-01 00:17:21 - browse：8337

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Rep. Raul Ruiz on the physician shortage and more

leisure time

WSS

With clinical trial data readouts, here's how to spot spin

Fetal surgery at risk from Dobbs and new abortion restrictions

Criminal prosecution for violating HIPAA: an emerging threat

Flagship Pioneering launches a new biotech in two countries

The EPA's new lead rule: How one expert crunched the numbers

Bird flu: Don't repeat Covid's 'health versus the economy' framing

leisure time

knowledge

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Fetal surgery at risk from Dobbs and new abortion restrictions

The cancer drug shortage isn’t new — and neither are the solutions

HIV vaccine remains elusive. Immunologists keep trying new ideas

Wildfire smoke exposes gaps in outdoor worker protections

BIO selects John Crowley as new CEO

Activists slam private health insurers over coverage restrictions

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Medical records are filled with copy

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Wikipedia

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Flagship Pioneering launches a new biotech in two countries

Pediatric cancer treatments threatened by a new FDA policy

Readers respond to H5N1 and livestock movements, and more

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

What don’t we know about an Alzheimer’s drug side effect?

focus

leisure time

knowledge

Wikipedia